Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Selected Treatment Schedules: Adenocarcinoma, Pancreas

Selected Treatment Schedules

2dd, twice daily; AUC, area under the concentration–time curve; BMI, body mass index; FU, fluorouracil; HER2, human epidermal growth factor receptor 2; FOLFIRI, folinic acid, fluorouracil and irinotecan; 5-FU, 5-fluorouracil.

Adenocarcinoma, Pancreas

(Neo)adjuvant	Palliative
4-weekly gemcitabine 1000 mg/m² d1, 8, 15^[25]	4-weekly gemcitabine 1000 mg/m², nab-paclitaxel 125 mg/m² d1, 8, 15^[26]
---	FOLFIRINOX: oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², 5-FU 400 mg/m² bolus, 5-FU 2400 mg/m²/46 h^[27]

References

25. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013; 310:1473–1481.

26. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691–1703.

27. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817–1825.